Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fluorouracil
Drug ID BADD_D00931
Description A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
Indications and Usage For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
Marketing Status approved
ATC Code L01BC02
DrugBank ID DB00544
KEGG ID D00584; D07974
MeSH ID D005472
PubChem ID 3385
TTD Drug ID D05LEO
NDC Product Code 62049-185; 16110-812; 16729-276; 68001-266; 16714-178; 25021-215; 51672-4063; 63323-117; 68083-293; 70700-187; 51927-1085; 62332-751; 38779-3185; 0378-8078; 68071-2961; 68083-270; 70700-188; 28105-421; 0378-4791; 68001-524; 68001-525; 68083-269; 12070-0002; 38779-0025; 59348-0055; 16729-542; 46708-751; 51672-4118; 70700-186; 70700-189; 51862-362; 68083-292; 49452-3175; 0187-5200; 51672-4062; 62991-1486; 0187-3204
UNII U3P01618RT
Synonyms Fluorouracil | 5FU | 5-FU | 5-Fluorouracil | 5 Fluorouracil | Fluoruracil | 5-FU Lederle | 5 FU Lederle | 5-FU Medac | 5 FU Medac | 5-HU Hexal | 5 HU Hexal | Adrucil | Carac | Efudix | Fluoro-Uracile ICN | Fluoro Uracile ICN | Efudex | Fluoroplex | Flurodex | Fluorouracil Mononitrate | Fluorouracil Monopotassium Salt | Fluorouracil Monosodium Salt | Fluorouracil Potassium Salt | Fluorouracil-GRY | Fluorouracil GRY | Fluorouracile Dakota | Dakota, Fluorouracile | Fluorouracilo Ferrer Far | Fluracedyl | Haemato-FU | Haemato FU | Neofluor | Onkofluor | Ribofluor | 5-Fluorouracil-Biosyn | 5 Fluorouracil Biosyn
Chemical Information
Molecular Formula C4H3FN2O2
CAS Registry Number 51-21-8
SMILES C1=C(C(=O)NC(=O)N1)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cerebrovascular disorder17.08.02.002; 24.03.05.002--Not Available
Cheilitis23.03.03.025; 07.05.01.0010.000404%
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.0090.001875%Not Available
Chest pain08.01.08.002; 02.02.02.011; 22.12.02.0030.005460%Not Available
Chills15.05.03.016; 08.01.09.0010.002279%
Choking22.12.03.0030.000184%Not Available
Cholangitis09.02.01.0020.000827%Not Available
Cholestasis09.01.01.0010.000460%Not Available
Cholinergic syndrome17.05.01.0020.000276%Not Available
Chromaturia20.02.01.0020.000551%
Circulatory collapse24.06.02.0010.000368%Not Available
Colitis07.08.01.0010.001195%
Colitis ischaemic24.04.08.012; 07.08.01.0040.000551%Not Available
Coma17.02.09.0010.000919%Not Available
Condition aggravated08.01.03.004--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Congenital anomaly03.02.01.001--Not Available
Conjunctival haemorrhage24.07.05.001; 06.07.01.0010.000184%Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Corneal oedema06.04.02.0010.000184%Not Available
Corneal perforation12.01.04.003; 06.06.03.0060.000184%Not Available
Coronary artery disease24.04.04.006; 02.02.01.0010.000276%Not Available
Coronary artery occlusion12.02.01.036; 24.04.04.013; 02.02.01.0060.000184%Not Available
Coronary artery stenosis12.02.01.037; 24.04.04.017; 02.02.01.0100.000368%Not Available
Coronary artery thrombosis24.01.05.002; 02.02.01.0070.000460%Not Available
Cutaneous vasculitis24.12.04.008; 23.06.02.001; 10.02.02.0030.000276%Not Available
Cyanosis02.11.04.004; 23.06.04.005; 24.03.01.007; 22.02.02.0070.000368%
Dacryocanaliculitis11.01.06.007; 06.04.04.010--Not Available
Deafness04.02.01.0010.000735%Not Available
Dehydration14.05.05.0010.001930%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 18 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene